Pierre Fabre Medicament
Clinical trials sponsored by Pierre Fabre Medicament, explained in plain language.
-
New hope for transplant patients with rare virus-driven cancer
Disease control Recruiting nowThis study tests a treatment called tabelecleucel for people who develop a rare, virus-linked cancer after an organ or stem cell transplant and whose cancer did not respond to standard therapy. About 115 participants will receive this cell therapy to see if it can shrink tumors a…
Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New hope for rare lung cancer mutations: first human trial launches
Disease control Recruiting nowThis study tests a new drug, STX-721, in people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if the drug can shrink tumors. About 251 participants will take the drug by mouth,…
Phase: PHASE1, PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New hope for hard-to-treat lung cancer: experimental drug targets resistant tumors
Disease control Recruiting nowThis study tests a new drug called STX-241 in people with advanced non-small cell lung cancer that has stopped responding to standard targeted therapies. The drug is designed to reach the brain and attack cancer cells with specific genetic changes. The trial will check safety, fi…
Phase: PHASE1, PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 18, 2026 12:06 UTC